X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-01-06 | ARWR | Hamilton James C | Chief Discovery, Trans Medicin | S - Sale | $19.82 | -32,729 | 272,122 | -11% | -$648,824 | ||||||
| M | 2025-01-06 | ARWR | O'Brien Patrick | COO, GC | S - Sale | $19.80 | -37,184 | 527,201 | -7% | -$736,059 | |||||
| M | 2025-01-06 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $19.77 | -45,167 | 455,433 | -9% | -$893,095 | |||||
2025-01-02 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $19.05 | -11,520 | 3,764,252 | 0% | -$219,456 | ||||||
2024-12-27 | ARWR | Olukotun Adeoye Y | Dir | S - Sale | $20.00 | -2,850 | 36,740 | -7% | -$57,000 | ||||||
2024-12-23 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $19.59 | -12,563 | 3,775,772 | 0% | -$246,109 | ||||||
2024-12-18 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $21.24 | -26,712 | 3,788,335 | -1% | -$567,486 | ||||||
| M | 2024-12-16 | ARWR | Waddill William D. | Dir | S - Sale | $21.97 | -7,495 | 40,378 | -16% | -$164,665 | |||||
| M | 2024-12-16 | ARWR | Given Douglas B | Dir | S - Sale | $21.91 | -5,547 | 124,167 | -4% | -$121,556 | |||||
2024-12-16 | ARWR | Vakiener Victoria | Dir | S - Sale | $21.91 | -8,994 | 21,211 | -30% | -$197,059 | ||||||
2024-07-02 | ARWR | Oliver Tracie | Chief Commercial Officer | S - Sale | $25.28 | -9,394 | 127,107 | -7% | -$237,480 | ||||||
2024-05-02 | ARWR | Vakiener Victoria | Dir | S - Sale | $23.31 | -1,799 | 30,205 | -6% | -$41,935 | ||||||
2024-04-01 | ARWR | Hamilton James C | Chief Discovery, Trans Medicin | S - Sale | $28.03 | -6,000 | 204,851 | -3% | -$168,180 | ||||||
| M | 2024-03-18 | ARWR | Lu Hongbo | Dir | P - Purchase | $27.66 | +3,000 | 33,680 | +10% | +$82,990 | |||||
2024-03-06 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $35.19 | -40,000 | 400,600 | -9% | -$1,407,600 | ||||||
| D | 2024-01-31 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $32.35 | -57,499 | 3,715,048 | -2% | -$1,860,019 | |||||
2024-01-12 | ARWR | Hamilton James C | Chief Discovery, Trans Medicin | S - Sale | $36.89 | -7,940 | 210,851 | -4% | -$292,904 | ||||||
2024-01-11 | ARWR | Given Douglas B | Dir | S - Sale | $38.06 | -2,911 | 129,711 | -2% | -$110,788 | ||||||
2024-01-11 | ARWR | Waddill William D. | Dir | S - Sale | $38.07 | -3,934 | 47,870 | -8% | -$149,759 | ||||||
2024-01-11 | ARWR | Ferrari Mauro | Dir | S - Sale | $38.06 | -3,147 | 60,778 | -5% | -$119,787 | ||||||
2024-01-11 | ARWR | Vakiener Victoria | Dir | S - Sale | $38.10 | -4,720 | 32,001 | -13% | -$179,813 | ||||||
2024-01-05 | ARWR | Oliver Tracie | Chief Commercial Officer | S - Sale | $33.89 | -74 | 136,501 | 0% | -$2,508 | ||||||
2024-01-05 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $35.27 | -16,104 | 440,600 | -4% | -$567,910 | ||||||
2024-01-05 | ARWR | San Martin Javier | Chief Medical Officer | S - Sale | $35.26 | -8,303 | 198,497 | -4% | -$292,804 | ||||||
| M | 2024-01-03 | ARWR | Hamilton James C | Chief Discovery/Trans Medicine | S - Sale | $34.69 | -38,443 | 218,791 | -15% | -$1,333,529 | |||||
| M | 2024-01-03 | ARWR | O'Brien Patrick | COO, GC | S - Sale | $34.36 | -33,190 | 464,385 | -7% | -$1,140,362 | |||||
2024-01-02 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $31.01 | -9,952 | 3,715,048 | 0% | -$308,637 | ||||||
2023-12-20 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $28.54 | -12,000 | 3,725,000 | 0% | -$342,480 | ||||||
2023-11-20 | ARWR | San Martin Javier | Chief Medical Officer | S - Sale | $28.80 | -19,700 | 131,800 | -13% | -$567,315 | ||||||
2023-10-25 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $24.21 | -24,338 | 3,737,000 | -1% | -$589,223 | ||||||
2023-09-28 | ARWR | Vakiener Victoria | Dir | S - Sale | $26.33 | -1,550 | 21,734 | -7% | -$40,812 | ||||||
| D | 2023-09-18 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $28.12 | -57,755 | 3,761,338 | -2% | -$1,624,223 | |||||
2023-07-03 | ARWR | Oliver Tracie | Chief Commercial Officer | S - Sale | $35.31 | -8,925 | 61,575 | -13% | -$315,142 | ||||||
2023-06-30 | ARWR | Hamilton James C | Chief Discovery/Trans Medicine | S - Sale | $35.53 | -3,000 | 188,484 | -2% | -$106,590 | ||||||
2023-06-27 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $36.20 | -15,000 | 381,704 | -4% | -$543,000 | ||||||
2023-05-05 | ARWR | Given Douglas B | Dir | S - Sale | $40.90 | -6,500 | 143,135 | -4% | -$265,850 | ||||||
| DM | 2023-05-03 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $39.32 | -104,928 | 3,761,338 | -3% | -$4,125,674 | |||||
2023-03-03 | ARWR | Olukotun Adeoye Y | Dir | S - Sale | $32.65 | -11,350 | 7,867 | -59% | -$370,578 | ||||||
2023-02-27 | ARWR | Given Douglas B | Dir | S - Sale | $32.62 | -875 | 149,635 | -1% | -$28,543 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |